For consumer media onlyFirst treatment option SKYCLARYS™ (omaveloxolone) for Australian's diagnosed with 'neurogenerative disease' Friedreich ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Insiders have been trading these 5 stocks: (($FSLY)), (($BIIB)), (($KR)), (($BE)) and (($PSTG)). Here is a breakdown of their ...

The stock's fall snapped a two-day winning streak.

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.

Harrow has entered into an agreement with Samsung Bioepis for the U.S. commercial rights to two ophthalmology biosimilars, ...

Biogen is expected to release its fiscal second-quarter earnings later this month, and analysts project a double-digit profit ...

More than half of drug launches fall short of forecasts. Engaging payers during trial design and capturing outcomes with real ...

Included in the agreement are ranibizumab-nuna 0.05 mL injection (BYOOVIZ), referencing LUCENTIS (ranibizumab), and ...

Samsung Bioepis has entered into a license, development and commercialization agreement with Harrow for its ophthalmology ...

Biogen notified Samsung Bioepis of its decision to terminate the 2019 Development and Commercialization Agreement within the US and Canada. Samsung Bioepis has been closely working with Biogen on the ...

Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics ...